Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Low return world a boon for VC

A number of institutional investors are proving the health sciences venture capital space holds significant potential for Australian investors, with funding from the likes of QIC and Hostplus driving major pharmaceutical developments.

Upgrade your subscription to access this article

And gain access to:
  • All archived news content
  • Access to the Financial Standard app
  • Home page news customisation
  • Financial Standard 's fortnightly newspaper
  • 25% discount on tickets to networking events
And more
Already A Subscriber?

Read more: QICHostplusHatchtechVCMarcus SimpsonBrandon Capital PartnersCommonwealth of AustraliaAravaxAustralian Private EquityAustralian SuperHESTAInformation TechnologyInnovation FoundationNexvetNovartis International forSam SiciliaSpinifex PharmaceuticalsStatewide SuperSydneyUnited StatesVenture Capital Association